Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Active Recombinant Human TIGIT Protein, His-tagged

Cat.No. : TIGIT-104H
Product Overview : Recombinant Human TIGIT Protein extracellular domain 22-138aa (signal peptide removed), fused with a C-terminal His tag, was expressed in CHO.
  • Specification
  • Gene Information
  • Related Products
Description : TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-10 and diminished the production of IL-12p40. In addition, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.
Source : CHO
Species : Human
Tag : His
Predicted N Terminal : Met 22
Form : Lyophilized from sterile PBS, pH 7.4.
Bio-activity : Measured by its ability to bind with human CD155-Fc in a functional ELISA. Measured by its ability to bind with mouse PVRFch in a functional ELISA.
Molecular Mass : The recombinant mature human TIGIT protein consists of 123 amino acids and has a calculated molecular mass of 13.5 KD.
Endotoxin : <1.0EU/ug, LAL method
Purity : >95% (SDS-PAGE)
Stability : Samples are stable for up to twelve months from date of receipt at -70ºC.
Storage : Store it under sterile conditions at -20ºC~-70ºC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution : It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.
Gene Name : TIGIT T cell immunoreceptor with Ig and ITIM domains [ Homo sapiens ]
Official Symbol : TIGIT
Synonyms : TIGIT; T cell immunoreceptor with Ig and ITIM domains; V set and immunoglobulin domain containing 9 , V set and transmembrane domain containing 3 , VSIG9, VSTM3; T-cell immunoreceptor with Ig and ITIM domains; DKFZp667A205; FLJ39873; V-set and transmembrane domain containing 3; V-set and immunoglobulin domain containing 9; Washington University cell adhesion molecule; V-set and transmembrane domain-containing protein 3; V-set and immunoglobulin domain-containing protein 9; VSIG9; VSTM3; WUCAM;
Gene ID : 201633
mRNA Refseq : NM_173799
Protein Refseq : NP_776160
MIM : 612859
UniProt ID : Q495A1
Chromosome Location : 3q13.31
Function : protein binding;

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (5)

Ask a question
In which types of cancers is TIGIT inhibition being investigated? 12/02/2022

TIGIT inhibitors are being studied in a range of cancers, including lung cancer, breast cancer, and melanoma, among others.

How is TIGIT relevant in autoimmune diseases? 05/14/2022

TIGIT is being explored as a potential target for treating autoimmune diseases by modulating immune responses to prevent excessive inflammation.

What clinical applications does TIGIT have in cancer therapy? 06/11/2020

TIGIT is being explored as a potential target for cancer immunotherapy, with drugs designed to block TIGIT and enhance the immune system's ability to attack cancer cells.

How does TIGIT differ from other immune checkpoint proteins like PD-1 and CTLA-4? 04/22/2020

TIGIT operates as an immune checkpoint, similar to PD-1 and CTLA-4, but it has distinct mechanisms of action and may regulate different aspects of the immune response.

Are there any potential side effects associated with TIGIT-targeted therapies? 01/12/2016

As with any immunotherapy, potential side effects may include immune-related adverse events such as inflammation in various organs, but the specific profile is still under investigation.

Customer Reviews (3)

Write a review
Reviews
11/25/2022

    With its well-characterized nature and availability in various formats, the TIGIT protein is an advantageous tool that aids researchers in achieving their scientific goals.

    08/05/2017

      Whether it's troubleshooting issues, optimizing experimental protocols, or providing detailed information about the protein, the manufacturer's support team is dedicated to helping researchers overcome any challenges they may encounter.

      05/21/2017

        The manufacturer also ensures that the TIGIT protein is well-characterized, with extensive documentation on its functional properties.

        Ask a Question for All TIGIT Products

        Required fields are marked with *

        My Review for All TIGIT Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends